Targeting pathways to improve treatment for Myelodysplastic Syndromes
Targeting PANoptotic pathways for Myelodysplastic Syndromes treatment
['FUNDING_R01'] · LOYOLA UNIVERSITY CHICAGO · NIH-11108604
This study is looking at new ways to treat Myelodysplastic Syndromes (MDS) by understanding how certain pathways in our cells affect blood production and could lead to leukemia, with the hope of finding better treatments to help improve your symptoms and overall health.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | LOYOLA UNIVERSITY CHICAGO (nih funded) |
| Locations | 1 site (MAYWOOD, UNITED STATES) |
| Trial ID | NIH-11108604 on ClinicalTrials.gov |
What this research studies
This research focuses on Myelodysplastic Syndromes (MDS), a group of diseases caused by abnormal blood cell production from mutated stem cells in the bone marrow. The study aims to explore new treatment strategies that target PANoptotic pathways, which are involved in cell death and survival. By understanding how these pathways affect blood cell production and the progression to acute myeloid leukemia (AML), the research seeks to develop more effective therapies that can alleviate symptoms and improve patient outcomes. Patients with MDS often experience severe symptoms due to low blood cell counts, and this research could lead to innovative treatments that address the root causes of the disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with Myelodysplastic Syndromes, particularly those experiencing severe symptoms related to low blood cell counts.
Not a fit: Patients with MDS who do not have mutations in the relevant pathways or those with advanced stages of acute myeloid leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for MDS, potentially reducing symptoms and preventing the progression to acute myeloid leukemia.
How similar studies have performed: While targeting apoptosis pathways is a novel approach, early clinical trials with splice inhibitors have shown promising results in similar patient populations.
Where this research is happening
MAYWOOD, UNITED STATES
- LOYOLA UNIVERSITY CHICAGO — MAYWOOD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHANG, JIWANG — LOYOLA UNIVERSITY CHICAGO
- Study coordinator: ZHANG, JIWANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.